Aspergillus osteomyelitis: review of 12 cases identified by the Prospective Antifungal Therapy Alliance registry.
A review of 12 patients with proven Aspergillus osteomyelitis was undertaken between July 2004 and October 2007. Aspergillus fumigatus was most commonly identified (n = 9). Voriconazole was commonly administered (11/12; 91.7%), and 9 (75.0%) underwent surgery. Seven (58.3%) responded to treatment, and 12-week mortality was 25.0% (3/12). Survival was improved with surgical intervention (P = 0.05).
Horn
David
D
Thomas Jefferson University, Philadelphia, PA, USA. david.horn@jefferson.edu
Sae-Tia
Sutthichai
S
Neofytos
Dionissios
D
D000328:Adult; D000368:Aged; D000935:Antifungal Agents / Q000627:therapeutic use; D001228:Aspergillosis / Q000175:diagnosis* / Q000188:drug therapy / Q000382:microbiology / Q000601:surgery; D001230:Aspergillus / Q000145:classification / Q000302:isolation & purification*; D001232:Aspergillus fumigatus / Q000145:classification / Q000302:isolation & purification; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010019:Osteomyelitis / Q000188:drug therapy / Q000382:microbiology* / Q000401:mortality / Q000601:surgery; D011743:Pyrimidines / Q000627:therapeutic use; D016896:Treatment Outcome; D014230:Triazoles / Q000627:therapeutic use; D065819:Voriconazole
D000935:Antifungal Agents; D011743:Pyrimidines; D014230:Triazoles; D065819:Voriconazole